■GC Biopharma announced on the 2nd that it has entered into a domestic co-marketing and distribution agreement for the oral COVID-19 treatment 'Paxlovid' (active ingredients: nirmatrelvir and ritonavir) with Pfizer Korea. Under this agreement, GC Biopharma will be responsible for the domestic distribution of Paxlovid starting in June. Both companies plan to engage in various activities from marketing to sales to enhance patient accessibility. In particular, they aim to maximize business synergy through their close relationship that has been ongoing since the co-marketing agreement for 'Genotropin' in 2005.
■Bukwang Pharmaceutical announced on the 2nd that it has launched 'Regadex' (active ingredients: ursodeoxycholic acid and diphenyl dimethyl dicarboxylate), a medication for liver disease. Regadex is Bukwang Pharmaceutical's first combination drug, released as part of an expansion of the Regaron line for liver disease. The components are ursodeoxycholic acid (UDCA) and diphenyl dimethyl dicarboxylate (DDB). UDCA has a mechanism of action that quickly normalizes aspartate aminotransferase (AST) levels with anti-inflammatory and antioxidant effects. DDB has the advantage of rapidly lowering alanine aminotransferase (ALT) levels. AST and ALT are commonly used indicators of liver health and are related to inflammation. When liver cells are damaged due to inflammation, these enzymes leak into the bloodstream, raising AST and ALT concentrations. According to the clinical results, Regadex normalizes ALT levels within 4 weeks and maintains significant results up to 24 weeks.
■Next Biomedical announced on the 2nd that one of its models for the vascular embolization device 'Nexsphere', namely 'Nexsphere-F', has received official approval to participate in the TAP (Total Product Life Cycle Advisory Program) from the U.S. Food and Drug Administration (FDA). The TAP program provides technical advice and strategic support throughout the entire development cycle of medical devices, operating in a limited manner by comprehensively considering technical innovation and applicability in medical practice. Nexsphere-F is a vascular embolization device that temporarily occludes blood vessels for therapeutic purposes. The company is preparing for clinical trials to obtain market approval and commercialization of Nexsphere-F in the U.S.
■Samjin Pharm announced on the 2nd that it will officially present its core pipeline and research achievements through an overseas biotech conference. First, from the 10th to the 12th, it will participate in the World ADC (Antibody-Drug Conjugate) Asia Summit in Incheon, where it will introduce its ADC pipeline and platform technologies. The key features include the SJA20 series with STING agonist payloads, the SJA70 series utilizing large anticancer drugs, and the self-developed ADC platform technology. Subsequently, from the 16th to the 19th (local time), it will participate in the 2025 BIO International Convention (BIO USA), the world's largest biotech event held in Boston, where it will promote technology transfer and joint development of pipelines focused on cancer and immune and inflammatory disease treatments. This partnership discussion will include solid tumor treatments SJN301 and SJN309, ADC treatments SJA20 and SJA70, and immune and inflammatory disease treatments SJN314.
■CHA Vaccine, a subsidiary of CHA Biotech, announced on the 2nd that it will participate in BIO USA from the 16th to the 19th. The focus will be on promoting technology transfers and joint development of the shingles prevention vaccine 'CVI-VZV-001' and the hepatitis B vaccine 'CVI-HBV-002'. It will set up a booth in the Korea Pavilion, jointly operated by the Korea Biotechnology Industry Organization and the Korea Trade-Investment Promotion Agency (KOTRA), to engage in partnering activities for the global market entry of its pipeline. The company also aims to explore joint development and technology transfer with regional partners in Southeast Asia, the Middle East, Europe, and South America. An official corporate presentation session and pitching event in the Korea Pavilion will also be held.
■Daewoong Pharmaceutical announced on the 2nd that it hosted the 'DEEP (Daewoong·DNC Medical-AEsthetic Expert Program) Symposium' in collaboration with DNC Aesthetics. Reflecting the characteristics of individuals in their 40s, where multiple aging symptoms such as decreased skin elasticity, volume loss, and localized fat occur simultaneously, optimized treatment strategies were heavily introduced. Notably, the core of the symposium was an audience participation program. Participants discussed treatment plans with speakers in a panel discussion and later participated in a 'dual live broadcast' session to directly verify the results. During this process, various combinations were shared using Daewoong's representative aesthetic products and actual clinical data, further clarifying the expected effects and strategies of the treatments.
■Boryung announced on the 2nd that it has published the 'Sustainable Management Report 2025', which outlines its ESG management strategy and achievement. This report contains the 2024 ESG management activities and results pursued under the vision of 'creating sustainable value for humanity'. Since 2022, Boryung has published annual reports, transparently disclosing achievements in environmental, social, and governance sectors. Last year, Boryung established a '2050 carbon neutrality roadmap' aiming for net zero by 2050 to enhance its environmental management, and prepared a 10-year management plan regarding six major environmental indicators, including greenhouse gas emissions and energy use.
■Ildong Pharmaceutical's comprehensive healthcare platform company, Saerom MS, announced on the 2nd that it promoted its non-face-to-face medical kiosk 'Saerodoc' at the '2025 Home Care Rehabilitation Welfare Exhibition'. 'Saerodoc' is an integrated solution device that enables remote video consultations with just simple operations at the installed location without having to visit a medical institution, as well as the transmission of prescriptions to designated pharmacies. Saerom MS explained that it has expanded its business scope to include non-face-to-face medical kiosks, based on its capabilities in healthcare sectors, thanks to its IT and platform-related technologies and experience in operating non-face-to-face medical mediation services (Hudak Care).
■Dongkook Pharmaceutical announced on the 2nd that its flagship brand 'Insadol' has won the Grand Prize in the gum medicine sector at the 2025 National Industrial Awards. Organized by the Industrial Policy Institute and sponsored by the Ministry of Trade, Industry and Energy and the Ministry of Small and Medium Enterprises and Startups, the National Industrial Awards selects companies, institutions, and brands that achieved outstanding performance in each industrial sector over the past year. Insadol was recognized for its continuous growth in the domestic gum medicine market, product innovation, public welfare campaign operations, and various global certification achievements, leading to its selection as the awardee in the gum medicine sector. Launched in 1983, Insadol is Dongkook Pharmaceutical's flagship brand, having developed and expanded various oral care products including 'Insadol Plus', which was the first to receive a patent for its composite ingredients, as well as Winflex toothpaste and Insadent denture cleaner.
■Roche Korea and Roche Diagnostics Korea announced on the 2nd that they successfully completed the employee-led donation campaign 'Children's Walk' to support underprivileged children. Now in its 22nd year, this event was initiated as a socially responsible activity involving employee participation to commemorate 'African Children's Day' (June 16) designated by UNICEF. Since 2003, over 100,000 employees worldwide have walked together each year to raise charitable funds to support educational, health, and medical welfare for underprivileged children. In Korea, Roche Korea and Roche Diagnostics Korea participate jointly in the campaign as 'One Roche' every year. The employee contributions raised from this campaign will be used for children's support projects in over 75 countries worldwide through Roche Group's global charity organization 'Re&Act (Roche Employee Action and Charity Trust)'.